Fonar Corp. (FONR) is a publicly traded company in the Healthcare — Medical - Equipment & Services industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
FONAR Corporation, together with its subsidiaries, engages in the designing, manufacturing, selling, and servicing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries in the United States. It operates in two segments: Medical Equipment, and Physician Management and Diagnostic Services.
Analysis Summary
Fonar Corp. reported revenue of $104.4M in the most recent fiscal year, growing at a 5-year CAGR of 4.0%. Net income reached $8.3M, with a 0.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 40.3%, operating margin 9.0%, net margin 6.4%. Free cash flow grew at -10.2% CAGR over 5 years.
At the current price of $19.09, FONR trades at a P/E of 18.90 and an ROE of 3.81%. Market capitalisation stands at $118M.
Balance sheet quality for FONR: current ratio of 8.4, net cash position of $17.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is decent: free cash flow of $7.4M represents 89% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $19.09 |
| Market Cap | $118M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 18.90 |
| Price / Book | 0.66 |
| EV / EBITDA | 6.47 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 3.81% |
| Return on Invested Capital | 3.59% |
| Return on Assets | 3.05% |
| Gross Margin | 40.26% |
| Operating Margin | 9.05% |
| Net Margin | 6.35% |
Financial Health
| Debt / Equity | 0.22 |
| Current Ratio | 9.18 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 2.33 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| FONR | Fonar Corp. | $118M | 18.90 | 0.66 | 3.8% |
| 0J5Q.L | Hologic, Inc. | $16.9B | 31.08 | 3.24 | 11.1% |
| LLY | Eli Lilly and Company | $1.1T | 38.55 | 30.35 | 92.6% |
| JNJ | Johnson & Johnson | $650.6B | 31.40 | 7.80 | 32.9% |
| ABBV | AbbVie Inc. | $466.0B | 77.13 | -129.2% | |
| 0QCV.L | AbbVie Inc. | $397.1B | |||
| 0QAH.L | Merck & Co., Inc. | $367.4B | 117.56 | 8.73 | 6.6% |
| MRK | Merck & Co., Inc. | $362.5B | 117.30 | 8.71 | 6.6% |
Price Performance
| 1 month | +0.00% |
| 3 months | +0.00% |
| Year-to-date | +2.86% |
| 1 year | +26.09% |
| 3 years | +19.16% |
| 5 years | +13.63% |
52-Week Range
| 52-week High | $19.16 |
| 52-week Low | $13.62 |
| Avg Volume (90d) | 76K |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 1999-03-18 | $0.0003 | 0.01% |
| 1998-12-16 | $0.0003 | 0.01% |
| 1998-09-15 | $0.0003 | 0.01% |
| 1998-05-13 | $0.0228 | 0.48% |
Related companies: APYX · ARTV · EDAP · HYPR · IFRX · LUNG · NSPR
Explore sector: Healthcare · Medical - Equipment & Services
More sections of FONR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks